Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guben Quyu Jiedu is a Traditional Chinese Medicine (TCM) formulation, primarily administered as a capsule, developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is indicated for the treatment of chronic obstructive pulmonary disease (COPD) and sleep apnea. The formula's name reflects its core therapeutic principles in TCM: "Guben" (strengthening the foundation/vital qi), "Quyu" (removing blood stasis), and "Jiedu" (detoxifying/clearing heat-toxins). In the context of respiratory disease, these actions are intended to improve lung function, reduce airway inflammation, and address the systemic effects of chronic hypoxia and stasis. It has been evaluated in clinical studies to assess its efficacy and safety in patients with overlapping COPD and sleep apnea symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guben Quyu Jiedu.